Ahu PAKDEMİRLİ, Caner KARACA, Tolga SEVER, Ezgi DAŞKIN, Asım LEBLEBİCİ, Türkan YİĞİTBAŞI, Yasemin BAŞBINAR

Carvacrol alters soluble factors in HCT-116 and HT-29 cell lines

Background/aim: Natural products are popular insights for researchers to investigate promising anti-cancer agents since some of these substances have lesser adverse effects restricting the treatment than traditional chemotherapeutic agents. A well-known monoterpene Carvacrol, widely consumed in Mediterranean cuisine and lower risks of cancer, has efficient anticancer effects. However, the mechanism of action is yet to be discovered. Materials and methods: The investigation aims to illuminate a new perceptive in the role of this substance on colorectal cancer treatment, by the means of differences in a well-defined range of soluble factors. Carvacrol effect on both HT-29 and HCT-116 cell lines was evaluated on proliferation and the IC50 values were calculated by the RTCA xCELLigence device. Then MAGPIX assay was performed to obtain the changes in soluble factors of the cell lines. Results: The Multiplexing assay suggests some of these factors were altered in favor of surviving and proliferation in aggressive cell line HCT-116 whereas they were altered against these characters in HT-29, were correlated with the increased IC50 concentration of HCT-116 in carvacrol treatment. Conclusion: The current study indicates that differences in the levels of these soluble factors could modulate the anticancer effect related to carvacrol.

Keywords:

Carvacrol, phytochemical, colon cancer, soluble factors,

PDF

___

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal for Clinicians. 2018; 68 (6): 394- 424. doi: 10.3322/caac.21492
2. Thélin C, Sikka S. Epidemiology of colorectal cancer — incidence, lifetime risk factors statistics, and temporal trends. In: Ettarh R (editor). Screening for Colorectal Cancer with Colonoscopy. Rijeka, Crotia: InTech; 2015. doi: 10.5772/61945
3. Haraldsdottir S, Einarsdottir HM, Smaradottir A, Gunnlaugsson A, Halfdanarson TR. Colorectal cancer-review. Laeknabladid 2014; 100 (2): 75-82.
4. Lee JG, McKinney KQ, Pavlopoulos AJ, Park JH, Hwang S. Identification of anti-metastatic drug and natural compound targets in isogenic colorectal cancer cells. Journal of Proteomics 2015; 113: 326-336. doi: 10.1016/j.jprot.2014.10.009
5. Greenlee H. Natural products for cancer prevention. Seminars in Oncology Nursing 2012; 28 (1): 29-44. doi: 10.1016/j. soncn.2011.11.004
6. Caputi L, Aprea E. Use of terpenoids as natural flavouring compounds in food industry. Recent Patents on Food, Nutrition & Agriculture 2011; 3 (1): 9-16.
7. Huang M, Lu JJ, Huang MQ, Bao JL, Chen XP et al. Terpenoids: natural products for cancer therapy. Expert Opinion on Investigational Drugs 2012; 21 (12): 1801-1818. doi: 10.1517/13543784.2012.727395
8. Berrino F, Muti P. Mediterranean diet and cancer. European Journal of Clinical Nutrition 1989; 43: 49-55.
9. Slamenová D, Horváthová E, Sramková M, Marsálková L. DNA-protective effects of two components of essential plant oils carvacrol and thymol on mammalian cells cultured in vitro. Neoplasma 2007; 54 (2): 108-112.
10. Salimei PS, Marfè G, Di Renzo L, Di Stefano C, Giganti MG et al. The interference of rosmarinic acid in the DNA fragmentation induced by osmotic shock. Frontiers in Bioscience 2007; 12: 1308-1317.
11. Fan K, Li X, Cao Y, Qi H, Li L et al. Carvacrol inhibits proliferation and induces apoptosis in human colon cancer cells. Anticancer Drugs 2015; 26 (8): 813-823. doi: 10.1097/ CAD.0000000000000263
12. Tolga S, Asım L, Altuğ K, Çilem B, Aybüke O et al. New insight of tumor microenvironment in non-small cell lung cancer. Journal of Basic and Clinical Health Sciences 2019, 3 (2): 113- 120. doi: 10.30621/jbachs.2019.625
13. Nagano M, Chastre E, Choquet A, Bara J, Gespach C et al. Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. American Journal of Physiology 1995; 268 (3 Pt 1): 431-42. doi: 10.1152/ ajpgi.1995.268.3.G431
14. Kim HR. Obesity-related colorectal cancer: The role of leptin. Annals of Coloproctology 2015; 31 (6): 209-210. doi: 10.3393/ ac.2015.31.6.209
15. Jürgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. British Journal of Cancer 2013; 108 (6): 1316-1323. doi: 10.1038/bjc.2013.79
16. Hong IS. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Experimental and Molecular Medicine 2016; 48 (7): e242. doi: 10.1038/ emm.2016.64
17. Oke-Altuntas F, Demirtas I. Real-time cell analysis of the cytotoxicity of origanumacutidens essential oil on HT-29 and HeLa cell lines. Turkish Journal Of Pharmaceutical Sciences 2017; 14 (1): 29-33 doi: 10.4274/tjps.40427
18. Kou B, Li Y, Zhang L, Zhu G, Wang X et al. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Experimental and Molecular Pathology 2004; 76 (2): 129-137.
19. Mahboob S, Ahn SB, Cheruku HR, Cantor D, Rennel E et al. A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes’ stages A-D colorectal cancers. Clinical Proteomics 2015; 12 (1): 10. doi: 10.1186/s12014-015-9081-x
20. Hoda MR, Keely SJ, Bertelsen LS, Junger WG, Dharmasena D et al. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. British Journal of Surgery 2007; 94 (3): 346-354. doi: 10.1002/bjs.5530
21. Ogunwobi OO, Beales IL. The anti.apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. International Journal of Colorectal Disease 2007; 22 (4): 401-409. doi: 10.1007/s00384-006-0181-y
22. Chen G, Han G, Shen B, Li Y. GM-CSF facilitates the development of inflammation-associated colorectal carcinoma. Oncoimmunology 2014; 3 (1): e28186. doi: 10.4161/onci.28186